Eusol Biotech Co.,Ltd. (TPEX:6652)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
6.15
-0.64 (-9.43%)
At close: Mar 3, 2026
Market Cap842.55M -18.0%
Revenue (ttm)370.00K
Net Income-37.78M
EPS-0.28
Shares Out137.00M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume235,802
Average Volume142,192
Open6.83
Previous Close6.79
Day's Range5.97 - 6.83
52-Week Range5.25 - 10.20
Beta-0.85
RSI40.06
Earnings DateMar 24, 2026

About Eusol Biotech

Eusol Biotech Co.,Ltd. focuses on research and development of new drugs for the treatment of nerve injuries. The company’s pipeline includes ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) for spinal cord injury, and SM-1, a 3-in-1 combination sleeping aid. It also offers small molecule drugs including EPS221, a selective serotonin reuptake inhibitor; EPS222, a calcium channel blocker for cardiovascular disease; EPS251, a drug for rheumatology/anti-inflammation; and EA2501, a drug for anticoagulation. The company was founded... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1994
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6652
Full Company Profile

Financial Performance

Financial Statements